![](/wp-content/uploads/2024/04/Screenshot-2024-04-23-at-4.39.40%E2%80%AFPM.png)
$599
Novartis Q1 ’24 Earnings; Vertex Partners with TreeFrog for T1DM Manufacturing
Two cardiometabolic-related news items have been observed: Novartis hosted its Q1 ’24 earnings call (press release; slides); and Vertex announced an exclusive licensing agreement with TreeFrog Therapeutics for TreeFrog’s proprietary cell manufacturing technology (view press release). Below, FENIX provides highlights and insights for the respective news items.